» Articles » PMID: 20971185

A Copper Chelate of Thiosemicarbazone NSC 689534 Induces Oxidative/ER Stress and Inhibits Tumor Growth in Vitro and in Vivo

Overview
Date 2010 Oct 26
PMID 20971185
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, a Cu(2+) chelate of the novel thiosemicarbazone NSC 689534 was evaluated for in vitro and in vivo anti-cancer activity. Results demonstrated that NSC 689534 activity (low micromolar range) was enhanced four- to fivefold by copper chelation and completely attenuated by iron. Importantly, once formed, the NSC 689534/Cu(2+) complex retained activity in the presence of additional iron or iron-containing biomolecules. NSC 689534/Cu(2+) mediated its effects primarily through the induction of ROS, with depletion of cellular glutathione and protein thiols. Pretreatment of cells with the antioxidant N-acetyl-l-cysteine impaired activity, whereas NSC 689534/Cu(2+) effectively synergized with the glutathione biosynthesis inhibitor buthionine sulfoximine. Microarray analysis of NSC 689534/Cu(2+)-treated cells highlighted activation of pathways involved in oxidative and ER stress/UPR, autophagy, and metal metabolism. Further scrutiny of the role of ER stress and autophagy indicated that NSC 689534/Cu(2+)-induced cell death was ER-stress dependent and autophagy independent. Last, NSC 689534/Cu(2+) was shown to have activity in an HL60 xenograft model. These data suggest that NSC 689534/Cu(2+) is a potent oxidative stress inducer worthy of further preclinical investigation.

Citing Articles

Review to Elucidate the Correlation between Cuproptosis-Related Genes and Immune Infiltration for Enhancing the Detection and Treatment of Cervical Cancer.

Pandey P, Ramniwas S, Pandey S, Lakhanpal S, Padmapriya G, Mishra S Int J Mol Sci. 2024; 25(19).

PMID: 39408933 PMC: 11477161. DOI: 10.3390/ijms251910604.


A Reversible Fluorescent Chemosensor for the Selective Detection of Cu and CN ions by Displacement Approach.

Viswanathamurthi P, Dhivya R, Kavitha V, Haribabu J, Echeverria C J Fluoresc. 2023; 34(4):1811-1819.

PMID: 37642776 DOI: 10.1007/s10895-023-03381-2.


Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes for Breast Cancer.

Wang N, Gu Y, Li L, Chi J, Liu X, Xiong Y J Inflamm Res. 2022; 15:3477-3499.

PMID: 35726216 PMC: 9206459. DOI: 10.2147/JIR.S357144.


New Cu Complexes with N-Sulfonamide Ligands: Potential Antitumor, Antibacterial, and Antioxidant Agents.

Hangan A, Turza A, Lucaciu R, Sevastre B, Pall E, Oprean L Molecules. 2022; 27(10).

PMID: 35630815 PMC: 9144936. DOI: 10.3390/molecules27103338.


Enhanced antitumor effect of L-buthionine sulfoximine or ionizing radiation by copper complexes with 2,2´-biquinoline and sulfonamides on A549 2D and 3D lung cancer cell models.

Cadavid Vargas J, Villa Perez C, Soria D, Guerci A, Di Virgilio A J Biol Inorg Chem. 2022; 27(3):329-343.

PMID: 35247094 DOI: 10.1007/s00775-022-01933-8.


References
1.
Berenson J, Matous J, Swift R, Mapes R, Morrison B, Yeh H . A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007; 13(6):1762-8. DOI: 10.1158/1078-0432.CCR-06-1812. View

2.
Kanzawa T, Zhang L, Xiao L, Germano I, Kondo Y, Kondo S . Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene. 2004; 24(6):980-91. DOI: 10.1038/sj.onc.1208095. View

3.
Wondrak G . Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal. 2009; 11(12):3013-69. PMC: 2824519. DOI: 10.1089/ars.2009.2541. View

4.
Trachootham D, Alexandre J, Huang P . Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009; 8(7):579-91. DOI: 10.1038/nrd2803. View

5.
Kaufman R . Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002; 110(10):1389-98. PMC: 151822. DOI: 10.1172/JCI16886. View